摘要: Those with cardiovascular disease or cerebrovascular who are prescribed low-dose aspirin to reduce the risk of a further thrombotic event advised take for rest their lives (1). But do they so? And if not, why not? discontinue, what disadvantages concerning events? advantages regarding reduced side effects such incidence upper gastrointestinal bleeding? finally, is overall cost health service discontinuation? In this edition Thrombosis and Haemostasis Cea Soriano et al. (2) describe attempts answer these questions. They used The Health Improvement Network (THIN) primary care database identify 39,513 patients aged 50–84 years during 2000–2007 received first prescription (75–300 mg/ day) secondary prevention, followed up see happened. summary, here found:
schattauer.de参考文章(22)
Aiko Tomiya, Shinya Goto, High on-treatment platelet reactivity (HPR): What does it mean, and does it matter? Thrombosis and Haemostasis. ,vol. 109, pp. 177- 178 ,(2013) , 10.1160/TH12-12-0910
L. A. Garcia Rodriguez, L. Cea Soriano, C. Hill, S. Johansson, Increased risk of stroke after discontinuation of acetylsalicylic acid A UK primary care study Neurology. ,vol. 76, pp. 740- 746 ,(2011) , 10.1212/WNL.0B013E31820D62B5
Ursula Overbeck, Heinz G. Endres, Christos Krogias, Horst Neubauer, Saskia H. Meves, Dose-dependent effect of early antiplatelet therapy in acute ischaemic stroke. Thrombosis and Haemostasis. ,vol. 107, pp. 69- 79 ,(2011) , 10.1160/TH11-06-0436
S. C. Fox, J. A. May, A. Shah, U. Neubert, S. Heptinstall, Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. Platelets. ,vol. 20, pp. 250- 259 ,(2009) , 10.1080/09537100902912451
D. S. Bachman, I. Sibon, J.-M. Orgogozo, Antiplatelet drug discontinuation is a risk factor for ischemic stroke Neurology. ,vol. 62, pp. 1187- 1189 ,(2004) , 10.1212/WNL.63.9.1761
L. A. Garcia Rodriguez, L. Cea-Soriano, E. Martin-Merino, S. Johansson, Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care BMJ. ,vol. 343, ,(2011) , 10.1136/BMJ.D4094
Antithrombotic Trialists' Collaboration, None, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ. ,vol. 324, pp. 71- 86 ,(2002) , 10.1136/BMJ.324.7329.71
Marzia Lotrionte, Giuseppe GL Biondi-Zoccai, The hazards of discontinuing acetylsalicylic acid therapy in those at risk of coronary artery disease Current Opinion in Cardiology. ,vol. 23, pp. 487- 493 ,(2008) , 10.1097/HCO.0B013E32830B5AFA
Elisa Martin-Merino, Johansson, Bueno, Garcia Rodriguez, Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease. Pragmatic and Observational Research. ,vol. 3, pp. 1- 9 ,(2012) , 10.2147/POR.S29557
Galia Spectre, Lisa Arnetz, Claes-Göran Östenson, Kerstin Brismar, Nailin Li, Paul Hjemdahl, Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thrombosis and Haemostasis. ,vol. 106, pp. 491- 499 ,(2011) , 10.1160/TH11-04-0216